Patients with proximal deep-vein thrombosis (DVT) often develop post-thrombotic syndrome (PTS; chronic leg pain, swelling, redness, and ulcers) despite anticoagulant therapy. Investigators in the ATTRACT trial hypothesized that rapid removal of the thrombus by pharmacomechanical catheter-directed thrombolysis would reduce the risk of PTS. A total of 692 patients with acute proximal DVT were randomly assigned to anticoagulation plus pharmacomechanical thrombolysis or anticoagulation only. No significant difference was observed in the rate of PTS between 6 and 24 months (47% versus 48%; risk ratio 0.96, 95% CI 0.82–1.11, P = 0.56) or in recurrent venous thromboembolism during the 24-month follow-up (12% versus 8%; P = 0.09), but pharmacomechanical thrombolysis was associated with an increased rate of major bleeding events within 10 days (1.7% versus 0.3%; P = 0.049).
References
Vedantham, S. et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N. Engl. J. Med. 377, 2240–2252 (2017)
Rights and permissions
About this article
Cite this article
Lim, G. Pharmacomechanical thrombolysis in DVT. Nat Rev Cardiol 15, 68 (2018). https://doi.org/10.1038/nrcardio.2017.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2017.215